ValuEngine downgraded shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) from a strong-buy rating to a buy rating in a report released on Thursday.

A number of other equities analysts have also issued reports on EGRX. Mizuho reduced their target price on Eagle Pharmaceuticals from $57.00 to $40.00 and set an underperform rating for the company in a research note on Thursday, July 27th. Royal Bank Of Canada reduced their target price on Eagle Pharmaceuticals from $94.00 to $81.00 and set an outperform rating for the company in a research note on Thursday, July 27th. Zacks Investment Research lowered Eagle Pharmaceuticals from a hold rating to a strong sell rating in a research note on Monday, July 31st. Piper Jaffray Companies set a $118.00 target price on Eagle Pharmaceuticals and gave the stock a buy rating in a research note on Tuesday, July 25th. Finally, BidaskClub lowered Eagle Pharmaceuticals from a hold rating to a sell rating in a research note on Sunday, July 16th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of Hold and an average target price of $84.00.

Shares of Eagle Pharmaceuticals (NASDAQ EGRX) traded up 0.84% during mid-day trading on Thursday, hitting $47.80. The company had a trading volume of 497,012 shares. The company has a market capitalization of $731.24 million, a price-to-earnings ratio of 7.51 and a beta of 1.31. The company has a 50-day moving average price of $73.55 and a 200-day moving average price of $77.30. Eagle Pharmaceuticals has a 1-year low of $46.10 and a 1-year high of $97.15.

Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its earnings results on Monday, May 8th. The specialty pharmaceutical company reported $1.42 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.44 by $0.02. The firm had revenue of $76.80 million during the quarter, compared to analysts’ expectations of $70.10 million. Eagle Pharmaceuticals had a return on equity of 79.25% and a net margin of 44.48%. The business’s revenue was up 159.5% on a year-over-year basis. During the same quarter last year, the business earned ($0.06) EPS. On average, equities analysts anticipate that Eagle Pharmaceuticals will post $3.38 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was published by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/08/06/eagle-pharmaceuticals-inc-egrx-cut-to-buy-at-valuengine.html.

In related news, CFO Pete A. Meyers purchased 350 shares of the business’s stock in a transaction on Monday, June 12th. The shares were bought at an average cost of $71.49 per share, with a total value of $25,021.50. Following the transaction, the chief financial officer now owns 350 shares of the company’s stock, valued at $25,021.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have acquired a total of 805 shares of company stock worth $61,790 over the last ninety days. 19.50% of the stock is owned by insiders.

Large investors have recently made changes to their positions in the company. BlackRock Inc. increased its stake in shares of Eagle Pharmaceuticals by 183,871.5% in the first quarter. BlackRock Inc. now owns 1,206,853 shares of the specialty pharmaceutical company’s stock valued at $100,097,000 after buying an additional 1,206,197 shares in the last quarter. Victory Capital Management Inc. increased its stake in shares of Eagle Pharmaceuticals by 24.3% in the first quarter. Victory Capital Management Inc. now owns 1,072,714 shares of the specialty pharmaceutical company’s stock valued at $88,971,000 after buying an additional 209,398 shares in the last quarter. Iridian Asset Management LLC CT increased its stake in shares of Eagle Pharmaceuticals by 1,804.5% in the first quarter. Iridian Asset Management LLC CT now owns 755,027 shares of the specialty pharmaceutical company’s stock valued at $62,622,000 after buying an additional 715,382 shares in the last quarter. First Eagle Investment Management LLC increased its stake in shares of Eagle Pharmaceuticals by 4.1% in the first quarter. First Eagle Investment Management LLC now owns 661,005 shares of the specialty pharmaceutical company’s stock valued at $54,824,000 after buying an additional 26,200 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Eagle Pharmaceuticals by 6.8% in the first quarter. Vanguard Group Inc. now owns 458,060 shares of the specialty pharmaceutical company’s stock valued at $37,991,000 after buying an additional 29,339 shares in the last quarter.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.